News
12-08-2015, 06:50 AM
OncoSec Medical Incorporated, a company developing DNA-based intratumoral cancer immunotherapies, today announced financial results for the first quarter of fiscal year ended July 31, 2016.
More... (http://www.news-medical.net/news/20151208/OncoSec-reports-net-loss-of-2470-million-for-first-quarter-of-fiscal-2016.aspx)
More... (http://www.news-medical.net/news/20151208/OncoSec-reports-net-loss-of-2470-million-for-first-quarter-of-fiscal-2016.aspx)